Literature DB >> 18991679

Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers.

David A Stein1.   

Abstract

RNA virus infections cause immense human disease burdens globally, and few effective antiviral drugs are available for their treatment. Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) are nuclease resistant and water-soluble single-stranded-DNA-analogues that can enter cells readily and act as steric-blocking antisense agents through stable duplex formation with complementary RNA. Recently there have been a number of publications documenting sequence-specific and dose-dependent inhibition of non-retroviral RNA virus infections by PPMO in both cell culture and murine experimental systems. PPMO have suppressed viral titers by several orders of magnitude in cell cultures, and have reduced viral replication in and/or increased survivorship of mice experimentally infected with poliovirus, coxsackievirus B3, dengue virus, West Nile virus, Venezuelan Equine encephalitis virus, respiratory syncytial virus, Ebola virus and influenza A virus. Along with evaluating PPMO efficacy and toxicity, these studies also explored PPMO mechanism of action, pharmacologic properties and the generation and characterization of resistant virus. Effective PPMO target sites in viral RNA have included regions of highly conserved sequence thought to be important in the pre-initiation or initiation of translation, or in long-range RNA-RNA interactions involved in viral RNA synthesis. These studies provide guidance for the design of steric-blocking antisense agents against RNA viruses, insights into viral molecular biology and novel strategies for the development of antiviral therapeutics. The purpose of this review is to summarize notable findings from the reports documenting antiviral activity by PPMO, with a focus on the specific regions of viral RNA that provided the most effective targets for PPMO-based inhibition of viral replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991679     DOI: 10.2174/138161208786071290

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  23 in total

1.  Dystrophin isoform induction in vivo by antisense-mediated alternative splicing.

Authors:  Sue Fletcher; Abbie M Adams; Russell D Johnsen; Kane Greer; Hong M Moulton; Steve D Wilton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

2.  Model systems for the study of human norovirus Biology.

Authors:  S Vashist; D Bailey; A Putics; I Goodfellow
Journal:  Future Virol       Date:  2009-07       Impact factor: 1.831

3.  Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors.

Authors:  Benjamin W Neuman; Lydia H Bederka; David A Stein; Joey P C Ting; Hong M Moulton; Michael J Buchmeier
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

4.  Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2.

Authors:  Eva Böttcher-Friebertshäuser; David A Stein; Hans-Dieter Klenk; Wolfgang Garten
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

5.  Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.

Authors:  David R Soto-Pantoja; Jeff S Isenberg; David D Roberts
Journal:  J Genet Syndr Gene Ther       Date:  2011-09-26

6.  Lessons learned from vivo-morpholinos: How to avoid vivo-morpholino toxicity.

Authors:  David P Ferguson; Lawrence J Dangott; J Timothy Lightfoot
Journal:  Biotechniques       Date:  2014-05-01       Impact factor: 1.993

7.  Therapeutics for postexposure treatment of Ebola virus infection.

Authors:  Marina Jerebtsova; Sergei Nekhai
Journal:  Future Virol       Date:  2015-03       Impact factor: 1.831

8.  Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity.

Authors:  Verena Krähling; David A Stein; Martin Spiegel; Friedemann Weber; Elke Mühlberger
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

Review 9.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

10.  Inhibition of intracellular growth of Salmonella enterica serovar Typhimurium in tissue culture by antisense peptide-phosphorodiamidate morpholino oligomer.

Authors:  Georgi M Mitev; Brett L Mellbye; Patrick L Iversen; Bruce L Geller
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.